Theravance Biopharma
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $18,754 | $16,868 | $14,256 | $14,503 |
Gross Profit | 18,754 | 16,868 | 4,302 | 12,970 |
EBITDA | -7,601 | -8,660 | -13,598 | -8,240 |
EBIT | -8,296 | -9,422 | -14,577 | -9,773 |
Net Income | -15,527 | -12,698 | -16,529 | -11,664 |
Net Change In Cash | 18,754 | 16,868 | 14,256 | 14,503 |
Free Cash Flow | -1,092 | -5,211 | -4,451 | -1,113 |
Cash | 37,797 | 23,378 | 46,345 | 53,835 |
Basic Shares | 48,942 | 49,038 | 48,747 | 48,283 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $64,381 | $57,424 | $51,346 | $55,311 |
Gross Profit | 64,381 | 16,803 | 44,757 | 48,025 |
EBITDA | -46,949 | -40,867 | -79,857 | -249,389 |
EBIT | -47,160 | -46,919 | -86,446 | -256,675 |
Net Income | -56,418 | -55,193 | -92,824 | -199,426 |
Net Change In Cash | 64,381 | 57,424 | 51,346 | 55,311 |
Cost of Revenue | 208,212 | 8,496 | ||
Free Cash Flow | -11,867 | -29,485 | -187,563 | -211,264 |
Cash | 37,797 | 39,545 | 298,172 | 89,959 |
Basic Shares | 48,847 | 55,303 | 73,591 | 69,461 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.05 |
2024-09-30 | -$0.05 |
2024-06-30 | -$0.28 |
2024-03-31 | -$0.24 |
